231 related articles for article (PubMed ID: 31233493)
1. Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B.
Simeon R; Jiang M; Chamoun-Emanuelli AM; Yu H; Zhang Y; Meng R; Peng Z; Jakana J; Zhang J; Feng H; Chen Z
PLoS Biol; 2019 Jun; 17(6):e3000311. PubMed ID: 31233493
[TBL] [Abstract][Full Text] [Related]
2. Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
Peng Z; Simeon R; Mitchell SB; Zhang J; Feng H; Chen Z
mSphere; 2019 Oct; 4(5):. PubMed ID: 31578248
[No Abstract] [Full Text] [Related]
3. Functional defects in
Gupta P; Zhang Z; Sugiman-Marangos SN; Tam J; Raman S; Julien JP; Kroh HK; Lacy DB; Murgolo N; Bekkari K; Therien AG; Hernandez LD; Melnyk RA
J Biol Chem; 2017 Oct; 292(42):17290-17301. PubMed ID: 28842504
[No Abstract] [Full Text] [Related]
4. Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection.
Chen P; Zeng J; Liu Z; Thaker H; Wang S; Tian S; Zhang J; Tao L; Gutierrez CB; Xing L; Gerhard R; Huang L; Dong M; Jin R
Nat Commun; 2021 Jun; 12(1):3748. PubMed ID: 34145250
[TBL] [Abstract][Full Text] [Related]
5. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.
Hernandez LD; Kroh HK; Hsieh E; Yang X; Beaumont M; Sheth PR; DiNunzio E; Rutherford SA; Ohi MD; Ermakov G; Xiao L; Secore S; Karczewski J; Racine F; Mayhood T; Fischer P; Sher X; Gupta P; Lacy DB; Therien AG
J Mol Biol; 2017 Apr; 429(7):1030-1044. PubMed ID: 28232034
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein receptor-related protein 1 is a CROPs-associated receptor for Clostridioides infection toxin B.
Guo S; Chen Y; Liu J; Zhang X; Liu Z; Zhou Z; Wei W
Sci China Life Sci; 2022 Jan; 65(1):107-118. PubMed ID: 34279819
[TBL] [Abstract][Full Text] [Related]
7. A neutralizing antibody that blocks delivery of the enzymatic cargo of
Kroh HK; Chandrasekaran R; Zhang Z; Rosenthal K; Woods R; Jin X; Nyborg AC; Rainey GJ; Warrener P; Melnyk RA; Spiller BW; Lacy DB
J Biol Chem; 2018 Jan; 293(3):941-952. PubMed ID: 29180448
[No Abstract] [Full Text] [Related]
8. Use of a neutralizing antibody helps identify structural features critical for binding of
Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
[No Abstract] [Full Text] [Related]
9. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
Orth P; Xiao L; Hernandez LD; Reichert P; Sheth PR; Beaumont M; Yang X; Murgolo N; Ermakov G; DiNunzio E; Racine F; Karczewski J; Secore S; Ingram RN; Mayhood T; Strickland C; Therien AG
J Biol Chem; 2014 Jun; 289(26):18008-21. PubMed ID: 24821719
[TBL] [Abstract][Full Text] [Related]
10. Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.
Carter GP; Chakravorty A; Pham Nguyen TA; Mileto S; Schreiber F; Li L; Howarth P; Clare S; Cunningham B; Sambol SP; Cheknis A; Figueroa I; Johnson S; Gerding D; Rood JI; Dougan G; Lawley TD; Lyras D
mBio; 2015 Jun; 6(3):e00551. PubMed ID: 26037121
[TBL] [Abstract][Full Text] [Related]
11. Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.
Hirota SA; Iablokov V; Tulk SE; Schenck LP; Becker H; Nguyen J; Al Bashir S; Dingle TC; Laing A; Liu J; Li Y; Bolstad J; Mulvey GL; Armstrong GD; MacNaughton WK; Muruve DA; MacDonald JA; Beck PL
Infect Immun; 2012 Dec; 80(12):4474-84. PubMed ID: 23045481
[TBL] [Abstract][Full Text] [Related]
12. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
13. Receptor Binding Domains of TcdB from
Henkel D; Tatge H; Schöttelndreier D; Tao L; Dong M; Gerhard R
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33255261
[TBL] [Abstract][Full Text] [Related]
14. Structural and functional insight into the interaction of Clostridioides difficile toxin B and FZD
Kinsolving J; Bous J; Kozielewicz P; Košenina S; Shekhani R; Grätz L; Masuyer G; Wang Y; Stenmark P; Dong M; Schulte G
Cell Rep; 2024 Feb; 43(2):113727. PubMed ID: 38308843
[TBL] [Abstract][Full Text] [Related]
15. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo.
Kordus SL; Kroh HK; Rodríguez RC; Shrem RA; Peritore-Galve FC; Shupe JA; Wadzinski BE; Lacy DB; Spiller BW
PLoS Pathog; 2023 Oct; 19(10):e1011496. PubMed ID: 37871122
[TBL] [Abstract][Full Text] [Related]
16. Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B.
Mansfield MJ; Tremblay BJ; Zeng J; Wei X; Hodgins H; Worley J; Bry L; Dong M; Doxey AC
PLoS Pathog; 2020 Dec; 16(12):e1009181. PubMed ID: 33370413
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of
Raeisi H; Azimirad M; Asadzadeh Aghdaei H; Zarnani AH; Abdolalizadeh J; Yadegar A; Zali MR
Microbiol Spectr; 2023 Sep; 11(5):e0531022. PubMed ID: 37668373
[TBL] [Abstract][Full Text] [Related]
18. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
[TBL] [Abstract][Full Text] [Related]
19. Structural dynamics of receptor recognition and pH-induced dissociation of full-length Clostridioides difficile Toxin B.
Jiang M; Shin J; Simeon R; Chang JY; Meng R; Wang Y; Shinde O; Li P; Chen Z; Zhang J
PLoS Biol; 2022 Mar; 20(3):e3001589. PubMed ID: 35324891
[TBL] [Abstract][Full Text] [Related]
20. Protease-stable DARPins as promising oral therapeutics.
Simeon RA; Zeng Y; Chonira V; Aguirre AM; Lasagna M; Baloh M; Sorg JA; Tommos C; Chen Z
Protein Eng Des Sel; 2021 Feb; 34():. PubMed ID: 34882774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
